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Unravelling the concept of Translational Medicine  
The term ‘Translational Medicine’ (TM), often used interchangeably with ‘Translational 
Research’ (TR), has gained momentum in recent years. The European Society for Translational 
Medicine (EUSTM) defines it as "an interdisciplinary branch of the biomedical field supported 
by three main pillars: benchside, bedside and community”. 
The main goal of TM is to bridge the gap between scientific research been developed in the lab 
bench and its possible future application at the clinical beside. This area of research is rapidly 
developing with the aim of accelerating the progression of a scientific discovery or finding into a 
diagnostic tool and/or therapy applied to human diseases to improve human health. In another 
words, TM acts as an umbrella bringing together basic and clinical research and encompasses 
numerous disciplines such as preclinical and clinical trial studies, intellectual property or 
regulation.  
 
 
The relevance of scientific collaborations: bridging the translational gap 
Whilst the importance and benefits of TM seem clear, significant challenges are also well-
recognised. One challenge in health care is that only few results are safely translated into effective 
clinical interventions. This lag between scientific discovery, and the translation of those 
discoveries into clinical practice, is known as the “translational gap”.  
An effective and open-minded scientific collaboration between basic scientists and clinicians is 
crucial to progress in TM. However, this is often a challenge due to the lack of communication, 
differences in education and training, and different goals and reward mechanisms between both 
professional groups. 
The work of basic scientists helps to understand biological processes and mechanisms of disease 
pathogenesis and progression. On the other side, clinical medicine is key to move results from 
clinical studies into clinical practice and to finally understand the efficacy and impact of the 
clinical product. But research does not proceed linearly and to improve the clinical relevance of 
the scientific findings, researchers should consider implementation at the initial steps of their 
research. Interdisciplinary teams formed by members with diverse professional backgrounds, 
would clearly minimise the translational gap whilst having a greater potential to benefit patients. 
Direct collaboration with pharmaceutical industry is also key to accelerate this progress. 
Academic health science centres, national societies and research institutes, have been aimed at 
encouraging qualified doctors to engage in research providing clinical scientists with the 
knowledge and tools needed to translate research discoveries into improved patient care. In the 
last years, some attention has been also given to support basic scientists performing translational 
research. Despite there are diverse national and European initiatives trying to speed clinical 
translation, many challenges and limitations still remain. Some barriers to TR are related to lack 
of sustained funding, regulatory issues such as ethics involved in human research, tissue banking 
or material transfer regulations and intellectual property rights, among others. 
This complex situation highlights the urgent need for a TR integrative platform which would 
serve to reduce the translational gap by promoting cutting-edge research with a clear focus on 
patient benefit.  
 
 
Ways to promote and improve a collaborative research: steps for Translational Medicine 
TR should create an educational, developmental and collaborative playground where scientists 
could design experimental approaches, while maintaining a view of their implications and how 
their work may help in the discovery of new therapies to achieve a public benefit. This fact alone 
initiates a positive dynamic with transformational potential that mobilises basic scientists, 
technologists, researchers and clinicians along the same axis of inquiry, creating a space for 
cooperation and collaboration. It is a disruptive idea indeed, because traditionally, scientists and 
clinicians have developed their work in disconnected departments as a result of their differences 
in professional language and culture, priorities and perspectives, preventing them from occupying 
a common space. 
The basis for TR support will come from several sources: Nationals Health Systems, industry, 
foundations, universities or medical centres, among others. It is important for hospitals and 
medical centres to build the necessary infrastructure that promotes TR locally, regionally, and 
nationally. Some centres may provide expertise in a given area that can be used by other centres. 
This may serve as a catalyst for investigator-initiated TR as well.  
Although the necessity for such an integration may seem obvious, it is anathema in most 
countries. The reality in most nations is that there are strict separations of revenue streams for 
hospitals on the one hand and for research resources that fund biomedical science on the other. 
The traditionally strict separation of both creates hurdles in the development pathway and often 
means that the translation from scientific discovery to marketable product and revenue generation 
is more time-consuming than necessary. 
Historically, the financial support of the pharmaceutical industry for academic institutions has 
taken the form of investigator-driven research grants. Industry has now realised the obsolescence 
of this strategy and is seeking to establish new models in which academic institutions are true 
partners in the drug-discovery process. 
To strengthen the foundations of TR in the near-term, companies could take actions such as 
defining metrics to assess TR impact, optimizing their governance to enable collaboration among 
TM, research, and development (pre-proof of concept and post-proof of concept), fostering 
knowledge-sharing across therapeutic areas, and finding and retaining the right talent.  
TR practices will integrate scientific (for example, biomarkers), technological (for example, in 
vitro testing modalities) and methodological (for example, in silico trials) advances to both, 
enabling more effective decision-making in R&D and enhancing coordination not only among 
functions within a biopharma company but also within industry, academic and government 
players.  
 
 
Impact  
The reclassification of pathological processes through the identification of molecular signatures 
creates a new classification of the human diseasome that is breaking down conceptual barriers 
and redefining how we understand disease. The repositioning of hierarchical classifications of 
diseases to molecular profiles, and not phenotypic manifestations, can only be strengthened if the 
biological information management systems are robust and efficient. With this in mind, the 
concept of FAIR data (Findable, Accessible, Interoperable, Reusable) has been developed, which 
should be a catalyst in the acceleration of outcome applicability. Future developments in TM 
should be built on this strategy, where biological data is managed in a meaningful way to support 
a fast-track development process. This is particularly important in the pre-implementation phase 
where technological outcomes from different experimental models will determine the successful 
implementation of health care interventions. 
Furthermore, the concept of TR extends beyond the domains of laboratory, not only to patients 
but to the community as a whole, necessitating health systems and operational research involving 
disciplines of epidemiology, behavior and social sciences, to incorporate the leads from the new 
research and technology in formulating public health policy and delivery strategy. 
In this way, the main impact of TR will be to translate the basic finding in clinical practice, but it 
will also generate publications, patents, spin out companies and new jobs, reported products and 
clinical trials, and more and more funding.  
 
 
There is no doubt that TM is key to accelerate scientific development and improve patient 
outcomes. Academic health science centres should promote the formation of complex 
interdisciplinary groups by facilitating the communication between professionals with different 
academic backgrounds. Translational researchers share a common goal: to combine disciplines, 
expertise, resources and techniques to promote enhancements in prevention, diagnosis, and therapies 
contributing to the improvement of patient care. 
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